// App-Quantinova.ai

SAT0226 (2018) : A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-rising dose study of the btk inhibitor tak-020 in healthy volunteers

Researchers

Presenter

  • E. Esfandiari

Principal Investigators

  • H. Gevorkyan

  • H. Faessel

  • Z. Zhao

  • K. Hanna

  • G. Smithson

  • J. Wagner

  • E. R. Fedyk

  • L. Mclean

Medical Centers

  • Takeda UK, London, United Kingdom

  • Parexel, Glendale CA

  • Takeda, Boston

  • Takeda

  • PRA, Deerfield IL

  • Samumed, San Diego, United States

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved